Mohammad Hojjat-Farsangi (M Hojjat-Farsangi)

Scopus Author ID Scopus Author ID Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 26

Top Venues

Expert opinion on therapeutic targets

Pharmaceutics

Immunological investigations

Biomedicines

Karolinska Institutet

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Karolinska Institutet Dec 31 2009

Sweden

Assistant Professor :: Oncology-Pathology

Bushehr University of Medical Sciences Jan 01 1998

Iran

Assistant Professor :: Department of Immunology

Publications

Mohammad Sadeghi, Atefeh Khodakarami, Armin Ahmadi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies. Expert opinion on therapeutic targets (2023)
Amineh Ghaderi, Mohammad Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat-Farsangi
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells. Pharmaceutics 15 (4) (2023)
Amineh Ghaderi, Mohammad Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat-Farsangi
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells. Pharmaceutics 15 (4) (2023)
Mohammad Sadeghi, Atefeh Khodakarami, Armin Ahmadi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies. Expert opinion on therapeutic targets 26 (12) (2023)
Mohammad Sadeghi, Atefeh Khodakarami, Armin Ahmadi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
The Prognostic and Therapeutic Potential of CTLA-4 in Hematological Malignancies. Expert opinion on therapeutic targets (2023)
Mohammad Sadeghi, Atefeh Khodakarami, Armin Ahmadi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies. Expert opinion on therapeutic targets 26 (12) (2023)
Mohammad Sadeghi, Atefeh Khodakarami, Armin Ahmadi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies. Expert opinion on therapeutic targets 26 (12) (2023)
Mohammad Sadeghi, Atefeh Khodakarami, Armin Ahmadi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies. Expert opinion on therapeutic targets 26 (12) (2023)
Amineh Ghaderi, Mohammad Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat-Farsangi
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells. Pharmaceutics 15 (4) (2023)
Mehrdad Fathi, Seyed-Mostafa Razavi, Mozhdeh Sojoodi, Armin Ahmadi, Farbod Ebrahimi, Afshin Namdar, Mohammad Hojjat-Farsangi, Sharareh Gholamin, Farhad Jadidi-Niaragh
Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions. Expert opinion on therapeutic targets 26 (11) (2022)
Mehrdad Fathi, Seyed-Mostafa Razavi, Mozhdeh Sojoodi, Armin Ahmadi, Farbod Ebrahimi, Afshin Namdar, Mohammad Hojjat-Farsangi, Sharareh Gholamin, Farhad Jadidi-Niaragh
Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions. Expert opinion on therapeutic targets 26 (11) (2022)
Mehrdad Fathi, Seyed-Mostafa Razavi, Mozhdeh Sojoodi, Armin Ahmadi, Farbod Ebrahimi, Afshin Namdar, Mohammad Hojjat-Farsangi, Sharareh Gholamin, Farhad Jadidi-Niaragh
Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions. Expert opinion on therapeutic targets (2022)
Amineh Ghaderi, Wen Zhong, Mohammad Ali Okhovat, Johanna Aschan, Ann Svensson, Birgitta Sander, Johan Schultz, Thomas Olin, Anders Österborg, Mohammad Hojjat-Farsangi, Håkan Mellstedt
A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells. Pharmaceutics 14 (10) (2022)
Mehrdad Fathi, Seyed-Mostafa Razavi, Mozhdeh Sojoodi, Armin Ahmadi, Farbod Ebrahimi, Afshin Namdar, Mohammad Hojjat-Farsangi, Sharareh Gholamin, Farhad Jadidi-Niaragh
Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions. Expert opinion on therapeutic targets 26 (11) (2022)
Mehrdad Fathi, Seyed-Mostafa Razavi, Mozhdeh Sojoodi, Armin Ahmadi, Farbod Ebrahimi, Afshin Namdar, Mohammad Hojjat-Farsangi, Sharareh Gholamin, Farhad Jadidi-Niaragh
Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions. Expert opinion on therapeutic targets 26 (11) (2022)
Mehrdad Fathi, Seyed-Mostafa Razavi, Mozhdeh Sojoodi, Armin Ahmadi, Farbod Ebrahimi, Afshin Namdar, Mohammad Hojjat-Farsangi, Sharareh Gholamin, Farhad Jadidi-Niaragh
Targeting the CTLA-4/B7 axes in glioblastoma: Preclinical evidence and clinical interventions. Expert opinion on therapeutic targets (2022)
Ramin Pourakbari, Forough Parhizkar, Mohammad Sadegh Soltani-Zangbar, Parisa Samadi, Majid Zamani, Leili Aghebati Maleki, Roza Motavalli, Ata Mahmoodpoor, Farhad Jadidi-Niaragh, Bahman Yousefi, Hossein Samadi Kafil, Mohammad Hojjat-Farsangi, Shahla Danaii, Mehdi Yousefi
Preeclampsia-Derived Exosomes Imbalance the Activity of Th17 and Treg in PBMCs from Healthy Pregnant Women. Reproductive sciences (Thousand Oaks, Calif.) (2022)
Walter Z Wang, Konstantin Shilo, Joseph M Amann, Alyssa Shulman, Mohammad Hojjat-Farsangi, Håkan Mellstedt, Johan Schultz, Carlo M Croce, David P Carbone
Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung. Cell death & disease 12 (6) (2021)
Amineh Ghaderi, Mohammad-Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat-Farsangi
A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1 + CLL cells. EJHaem 2 (3) (2021)
Parisa Sarvarian, Parisa Samadi, Elham Gholipour, Karim Shams Asenjan, Mohammad Hojjat-Farsangi, Roza Motavalli, Farhad Motavalli Khiavi, Mehdi Yousefi
Application of Emerging Plant-Derived Nanoparticles as a Novel Approach for Nano-Drug Delivery Systems. Immunological investigations (2021)
Amin Kamrani, Mohammad Sadegh Soltani-Zangbar, Sadaf Shiri, Yousef Yousefzadeh, Ramin Pourakbari, Leili Aghebati Maleki, Amir Mehdizadeh, Shahla Danaii, Farhad Jadidi-Niaragh, Bahman Yousefi, Hossein Samadi Kafil, Mohammad Hojjat-Farsangi, Roza Motavalli, Mohammadali Zolfaghari, Mostafa Haji-Fatahaliha, Ata Mahmoodpoor, Javad Ahmadian Heris, Asma Emdadi, Mehdi Yousefi
TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4+ T cells in Preeclampsia Patients. Immunological investigations (2021)
Abdolkarim Sheikhi, Mohammad Hojjat-Farsangi
An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein. Human vaccines & immunotherapeutics 17 (1) (2020)
Amineh Ghaderi, Amir Hossein Daneshmanesh, Ali Moshfegh, Parviz Kokhaei, Jan Vågberg, Johan Schultz, Thomas Olin, Sara Harrysson, Karin E Smedby, Elias Drakos, Georgios Z Rassidakis, Anders Österborg, Mohammad Hojjat-Farsangi, Håkan Mellstedt
ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. Biomedicines 8 (6) (2020)
Ghasem Ghalamfarsa, Mohammad Hossein Kazemi, Sahar Raoofi Mohseni, Ali Masjedi, Mohammad Hojjat-Farsangi, Gholamreza Azizi, Mehdi Yousefi, Farhad Jadidi-Niaragh
CD73 as a potential opportunity for cancer immunotherapy. Expert opinion on therapeutic targets 23 (2) (2018)
Mohammad Hojjat-Farsangi, A H Daneshmanesh, A S Khan, J Shetye, F Mozaffari, P Kharaziha, L-S Rathje, P Kokhaei, L Hansson, J Vågberg, S Byström, E Olsson, C Löfberg, C Norström, J Schultz, M Norin, T Olin, A Österborg, H Mellstedt, A Moshfegh
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Leukemia 32 (10) (2018)
Solmaz Shirjang, Nazila Alizadeh, Behzad Mansoori, Ata Mahmoodpoor, Hossein Samadi Kafil, Mohammad Hojjat-Farsangi, Mehdi Yousefi
Promising immunotherapy: Highlighting cytokine-induced killer cells. Journal of cellular biochemistry 120 (6) (2018)

Mohammad Hojjat-Farsangi.css-eqlu8i{font-size:small;padding-left:4px;} (M Hojjat-Farsangi)

Publication Activity (10 Years)

Top Topics

Top Venues

Mohammad Hojjat-Farsangi (M Hojjat-Farsangi)